Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
May, 2026
May 2026
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Raza Ur Rehman on Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B
Raza Ur Rehman/LikedIn
Jan 2, 2026, 08:47

Raza Ur Rehman on Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B

Raza Ur Rehman, Bachelor of Medicine and Surgery at Shaikh Khalifa bin Zayed Al Nahyan Medical and Dental College, shared on LinkedIn:

”Publication Alert

Thrilled to share that our Open Access commentary has been published in Health science Reports (Wiley )

Rebalancing Hemostasis: Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B

Health Science Reports | Volume 9, Issue 1
(e71702)

Raza Ur Rehman, Rida Fatima, Aymar AKILIMALI

Published: 29 December 2025

This article explores Fitusiran, a groundbreaking RNAi-based antithrombin-targeting therapy, marking a paradigm shift toward factor-independent prophylaxis in hemophilia management.

• Read here.

Honored to contribute to the evolving landscape of hemophilia therapeutics and RNA-based medicine.

Feedback and discussions are most welcome!”

Article: Rebalancing Hemostasis: Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B

Authors: Raza Ur Rehman, Rida Fatima, Aymar Akilimali

Raza Ur Rehman on Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B

Stay updated on all scientific advances with Hemostasis Today.

Aymar Akilimali bleeding disorders Fitusiran Health Hematology Hemophilia Hemostasis Hemostasis Today Medicine Raza Ur Rehman Rida Fatima RNAi thrombosis
NewsFeed